National Breakthrough Pain Study

Narayana, Arvind; Katz, Nathaniel; Shillington, Alicia C.; Stephenson, Judith J.; Harshaw, Qing; Frye, Carla B.; Portenoy, Russell K.

doi:10.1097/01.j.pain.0000460305.41078.7d

Cited by 32 publications

(36 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En nuestro estudio, la prevalencia de DI fue del 36 %, porcentaje inferior a las cifras del 48 al 80 % halladas en estudios previos (5,6,8,11,15). Esta menor prevalencia estaría en consonancia con el mayor conocimiento del tema.…”

Section: Discussionunclassified

“…En este sentido, los trabajos realizados en consultorios ambulatorios mostraron las tasas de prevalencia más bajas (5,9,16,19). Otros estudios conjeturan que los especialistas en dolor pueden estar más calificados para reconocer esta afección clínica (20) que otros especialistas médicos o entrevistadores no médicos (5,8).…”

Section: Discussionunclassified

“…En cuanto a la caracterización del DI en nuestra muestra, la localización más frecuente fue lumbar, coincidiendo con trabajos previos (8,13); de igual manera, el número de episodios diarios (media 2) y la duración de los mismos (> 30 minutos en el 53 % de los pacientes) es similar al de otros estudios en pacientes crónicos no oncológicos (5,6,8,11,21), mientras que la tipología (espontáneo e incidental), mostró un porcentaje similar, en línea con estudios previos realizados en DI oncológico (21,22).…”

Section: Discussionunclassified

“…Sin embargo, a pesar de todo ello, existe un claro consenso en los atributos clave del DI (5-9,15), y en que su presencia supone una pesada carga para el sistema de salud, afectando negativamente a la calidad de vida tanto de los pacientes como de sus cuidadores (8,9,13,15).…”

Section: Introductionunclassified

See 3 more Smart Citations

Estudio CRONO: prevalencia del dolor irruptivo en pacientes con dolor crónico no oncológico en Andalucía, España.

Rodriguez-Lopez

Torres-Morera

Herrera-Silva

et al. 2017

Rev. Soc. Esp. Dolor.

View full text Add to dashboard Cite

Section: Discussionunclassified

Section: Introductionunclassified

See 2 more Smart Citations

Estudio CRONO: prevalencia del dolor irruptivo en pacientes con dolor crónico no oncológico en Andalucía, España.

Rodriguez-Lopez

Torres-Morera

Herrera-Silva

et al. 2017

Rev. Soc. Esp. Dolor.

View full text Add to dashboard Cite

“…The GAD-7 assesses general anxiety in primary care patients [28, 29]. High correlations with disability measures were found [30].…”

Section: Methodsmentioning

confidence: 99%

Design, construction, and technical implementation of a web-based interdisciplinary symptom evaluation (WISE) - a heuristic proposal for orofacial pain and temporomandibular disorders

et al. 2016

View full text Add to dashboard Cite

BackgroundMedical symptoms independent of body location burden individuals to varying degrees and may require care by more than one expert. Various paper and computer-based tools exist that aim to comprehensively capture data for optimal clinical management and research.MethodsA web-based interdisciplinary symptom evaluation (WISE) was newly designed, constructed, and technically implemented. For worldwide applicability and to avoid copyright infringements, open source software tools and free validated questionnaires available in multiple languages were used. Highly secure data storage limits access strictly to those who use the tool for collecting, storing, and evaluating their data. Concept and implementation is illustrated by a WISE sample tailored for the requirements of a single center in Switzerland providing interdisciplinary care to orofacial pain and temporomandibular disorder patients.ResultsBy combining a symptom- burden checklist with in-depth questionnaires serving as case-finding instruments, an algorithm was developed that assists in clarifying case complexity and need for targeted expert evaluation. This novel modular approach provides a personalized, response-tailored instrument for the time- and cost-effective collection of symptom-burden focused quantitative data. The tool includes body drawing options and instructional videos. It is applicable for biopsychosocial evaluation in a variety of clinical settings and offers direct feedback by a case report summary.ConclusionsIn clinical practice, the new instrument assists in clarifying case complexity and referral need, based on symptom burden and response –tailored case finding. It provides single-case summary reports from a biopsychosocial perspective and includes graphical symptom maps. Secure, centrally stored data collection of anonymous data is possible. The tool enables personalized medicine, facilitates interprofessional education and collaboration, and allows for multicenter patient-reported outcomes research.

show abstract

Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS‐MS study

Mercadante

Adile

Masedu

et al. 2018

European Journal of Pain

View full text Add to dashboard Cite

Background Controversies exist about the choice and the doses of opioid medication in breakthrough cancer pain (BTcP). Methods The aim was to assess factors influencing the use and the doses of opioids prescribed for BTcP. There was performed a secondary analysis of a national, multicentre study that involving 32 centres performed in patients having BTcP. Diagnosis of BTcP was based on a definite algorithm. Patients using opioids for background pain and for BTcP were selected. Average pain intensity and opioids used for background pain and BTcP, and adverse effects were assessed, as well as patient’s satisfaction and the grade of mucositis. Results The analysis was performed in 2,771 patients. Opioid doses given for BTcP were significantly associated with those given for background pain. No relationship between adverse effects and the use and the doses of opioids used for BTcP was found. Drugs and doses were not correlated to the grade of oral mucositis. Nasal fentanyl preparations provided the fastest meaningful pain relief in comparison with other fentanyl transmucosal preparations or morphine preparations (P = 0.000). The majority of patients were satisfied with opioid medications given for BTcP. Only 2.8% of patients reported adverse effects related to opioid medication used for BTcP. Age and gender were independently associated with dosages of some fentanyl products. Conclusions Opioids for BTcP were effective and safe in a large sample of cancer patients with different stages of disease. Doses of opioids proportional to doses used for background pain seem to guarantee both efficacy and safety. Significance The use of opioids for breakthough cancer pain was effective and safe in a large sample of advanced cancer patients recruited in different stages of disease and settings. Doses of opioids proportional to opioid doses used for background analgesia, seem to guarantee both effectiveness and safety.

show abstract

National Breakthrough Pain Study

Cited by 32 publications

References 22 publications

Estudio CRONO: prevalencia del dolor irruptivo en pacientes con dolor crónico no oncológico en Andalucía, España.

Estudio CRONO: prevalencia del dolor irruptivo en pacientes con dolor crónico no oncológico en Andalucía, España.

Design, construction, and technical implementation of a web-based interdisciplinary symptom evaluation (WISE) - a heuristic proposal for orofacial pain and temporomandibular disorders

Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS‐MS study

Contact Info

Product

Resources

About